https://pittplusme.org/study/2275
National Institutes of Health - HVTN 303 - Vaccines in Healthy Adults (Pro00061855)
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Are you 18-50 and HIV-negative? You may be able to participate in a study to help test three experimental HIV vaccines. If eligible for this study, participation will involve about 12-25 visits over approximately 1-2 years. Compensation is provided.
IRB: STUDY22050049
- "National Institutes of Health - HVTN 303, A Phase 1, Open-Label Clinical Trial to Evaluate Safety, Tolerability, and Immunogenicity of Adjuvanted HIV-1 Fusion Peptide Conjugate Vaccine (VRC-HIVVCP0108-00-VP) Alone or in Prime-Boost Regimens with Adjuvanted HIV-1 Envelope Trimer 4571 (VRC-HIVRGP096-00-VP) and HIV-1 Trimer 6931 (VRCHIVRGP0106- 00-VP) Vaccines in Healthy Adults (Pro00061855)"
AGE:
18-50
DURATION:
1-2 years (depending on group)
VISITS:
12-25 (depending on group)
COMPENSATION:
At least $675
SHARE STUDY
MEET THE RESEARCHER
Madhu Choudhary
Madhu Choudhary is an Associate Professor in the Division of Infectious Diseases in the Department of Medicine at the University of Pittsburgh. A graduate of Maulana Azad Medical College, Dr. Choudhary’s research interests include HIV and viral hepatitis therapeutic clinical trials.